High-resolution x-ray diffraction has been used to analyze the type and density of threading dislocations in a series (0001)-oriented GaN epitaxial film. Photoluminescence (PL) and carrier mobility of the films are measured at room temperature. The intensities of both the band edge (3.42 eV) peak and yellow luminescence (YL) are strongly related to the threading dislocation density of the GaN films. But different types of dislocations show different relationship with the intensities of PL and YL. The fundamental correlation is found not only between the interaction of edge- and screw-type dislocations and the carrier mobility but also between the interaction and the intensities of both the band edge peak and the YL.

No abstract

No abstract

Background and Objective: Immune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors may have synergistic effects in elderly patients with advanced driver-negative NSCLC, but its true efficacy remains unclear. In addition, chemotherapy tolerance in elderly NSCLC patients is poor, and the precise identification of the population that may benefit from ICIs combined with angiogenesis inhibitors is also the focus of current research. Methods: We retrospectively compared the efficacy and safety of ICIs combined with or without antiangiogenic agents in elderly patients with advanced driver-gene negative NSCLC ≥65 years of age in the Cancer Center of Suzhou Hospital Affiliated to Nanjing Medical University. The primary endpoint was PFS. Secondary endpoints were OS, ORR, and immune-related adverse events (irAEs). Results: A total of 36 patients in the IA group (immune checkpoint inhibitors plus angiogenesis inhibitors group) and 43 patients in the NIA group (immune checkpoint inhibitors without angiogenesis inhibitors group) were enrolled in the study between January 1, 2019 and December 31, 2021. The median follow-up time for patients in the IA group and NIA group was 18.2 months (95%CI: 14 - 22.5 months) and 21.4 months (95%CI: 16.7 -26.1 months), respectively. The median PFS and median OS were longer in the IA group compared to the NIA group (8.1 months vs 5.3 months; HR for PFS: 0.778, 95%CI: 0.474-1.276, P=0.32; NA vs 30.9 months; HR for OS: 0.795, 95%CI: 0.396-1.595, P=0.519). There were no significant differences in median PFS and median OS between the two groups. Subgroup analysis showed that patients in the IA group had significantly longer PFS in the subgroup with PD-L1 expression ≥50% ( P =0.017), and the association between different groups and disease progression was still different in the two subgroups ( P for interaction = 0.002). There was no significant difference in ORR between the two groups (23.3% vs 30.5%, P =0.465). The incidence of irAEs in the IA group was lower than that in the NIA group (39.5% vs 19.4%, P =0.05), and the cumulative incidence of treatment interruptions due to irAEs was significantly reduced ( P =0.045). Conclusion: In elderly patients with advanced driver-negative NSCLC, the addition of antiangiogenic agents to ICIs therapy did not provide significant clinical benefit, but the incidence of irAEs and treatment interruptions due to irAEs was significantly reduced. In the subgroup analysis, we found that the clinical benefit of this combination therapy was observed in patients with PD-L1 expression ≥50%, which warrants further exploration.